May 29, 2025
Stealth BioTherapeutics Announces "Path Forward" Despite Disappointing Delay for Ultra-rare Barth Syndrome
Apr 29, 2025
Stealth BioTherapeutics Announces Delay in FDA Action Date for Barth Syndrome Application
Apr 24, 2025
Stealth BioTherapeutics to Present New Bevemipretide Data at ARVO Annual Meeting
Jan 23, 2025
Stealth BioTherapeutics Announces PDUFA Action Date Extension for Elamipretide to Treat Patients with Barth Syndrome
Sep 27, 2024
Stealth BioTherapeutics to Present at UBS Virtual Ophthalmology Day
Sep 18, 2024
Stealth BioTherapeutics Presents New Bevemipretide (SBT-272) Data at Keystone Symposium Targeting Dry Age-Related Macular Degeneration
Sep 12, 2024
Stealth BioTherapeutics Announces Participation at Upcoming Ophthalmology Conferences
Sep 11, 2024
Stealth BioTherapeutics Awarded Grant from Friedreich's Ataxia Research Alliance to Develop Investigational Mitochondrial Therapeutic SBT-589 for Friedreich's Ataxia
Sep 09, 2024
Stealth BioTherapeutics Announces FDA Advisory Committee Meeting to Review Elamipretide for Barth Syndrome Treatment
Jul 29, 2024
Stealth BioTherapeutics Completes Mid-Cycle Review Meeting on Elamipretide for the Treatment of Barth Syndrome
Jun 05, 2024
Stealth BioTherapeutics Announces First Patient Enrolled in Global Phase 3 Clinical Program for Elamipretide in Patients with Dry Age-Related Macular Degeneration
May 07, 2024
STEALTH BIOTHERAPEUTICS' BARTH SYNDROME NDA RECEIVES PRIORITY REVIEW DESIGNATION
Apr 08, 2024
STEALTH BIOTHERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR ELAMIPRETIDE FOR THE TREATMENT OF BARTH SYNDROME
Mar 19, 2024
Stealth BioTherapeutics Presents Data of Novel Compound, SBT-589, in Friedreich's Ataxia Cardiac Models at the Wellcome Trust Mitochondrial Medicine Conference
Feb 23, 2021
Stealth BioTherapeutics Completes Enrollment of Phase 2 Study in Dry Age-Related Macular Degeneration with Geographic Atrophy
Jan 07, 2021
Stealth BioTherapeutics to Participate in Upcoming January Investor Conferences
Jan 05, 2021
Stealth BioTherapeutics Granted Pre-NDA Meeting For Elamipretide As A Treatment For Cardiomyopathy In Barth Syndrome
Dec 07, 2020
Stealth BioTherapeutics Announces Appointment of Eve E. Slater, M.D., F.A.C.C. to its Board of Directors
Nov 20, 2020
Stealth BioTherapeutics Announces $3.2 Million Registered Direct Offering
Oct 19, 2020
Stealth BioTherapeutics Announces Poster Presentation at American Society of Human Genetics (ASHG) Virtual Annual Meeting